Corporate News     14-Dec-22
Biocon initiates clinical study of Itolizumab for Ulcerative Colitis in India
Biocon announced the initiation of the clinical study of Itolizumab in patients with Ulcerative Colitis (UC) in India, in collaboration with Equillium Inc. This is a phase two randomized, double-blind, parallel-group, placebo and active-controlled (adalimumab), two treatment period study to evaluate the safety and efficacy of Itolizumab for the induction of remission in biologics naïve patients with moderate to severely active UC.

Having obtained approval from the Drugs Controller General of India (DCGI), the study will cover several tertiary hospitals specialized in handling UC cases. The first patient who intended to participate in the study was screened on 01 December 2022.

Previous News
  Biocon Biologics set to introduce YESAFILI®, a proposed biosimilar to EYLEA® in Canadian market
 ( Corporate News - 04-Mar-24   09:30 )
  Biocon surges after signing exclusive licensing deal for Liraglutide with Handok
 ( Hot Pursuit - 24-May-24   09:45 )
  Biocon arm completes integration of Viatris biosimilars biz
 ( Hot Pursuit - 07-Sep-23   09:45 )
  Biocon Ltd spurts 1.11%, gains for five straight sessions
 ( Hot Pursuit - 24-Aug-23   13:01 )
  Biocon
 ( Results - Analysis 09-Aug-24   10:19 )
  Biocon to hold AGM
 ( Corporate News - 30-Apr-22   16:02 )
  Biocon Biologics receives EU GMP certificate for new facility in Bengaluru
 ( Corporate News - 05-Jul-22   20:03 )
  Benchmarks trade falt; oil & gas shares rally for 9th day in row
 ( Market Commentary - Mid-Session 24-May-24   12:33 )
  Biocon Ltd spurts 1.38%
 ( Hot Pursuit - 22-Mar-21   13:05 )
  Biocon Vice-Chairman resigns
 ( Corporate News - 23-Jul-21   13:46 )
  Biocon Ltd up for fifth session
 ( Hot Pursuit - 06-Feb-24   13:00 )
Other Stories
  GAIL (India) signs MoU with AM Green
  04-Oct-24   19:27
  EaseMyTrip.com resumes bookings to the Maldives
  04-Oct-24   19:25
  BLS completes acquisition of Dubai-based Citizenship Invest
  04-Oct-24   19:23
  Insecticides India launches new maize herbicide 'Torry Super'
  04-Oct-24   19:21
  Landmark Cars receives LoI from Mercedes-Benz India
  04-Oct-24   19:19
  Astra Microwave Products receives affirmation in credit ratings from CRISIL
  04-Oct-24   19:16
  Supreme Petrochem receives affirmation in credit ratings
  04-Oct-24   19:10
  Astec LifeSciences director resigns
  04-Oct-24   19:08
  Board of Gravita India approves change in directorate
  04-Oct-24   19:05
  Board of Gravita India approves fund raising up to Rs 1,000 cr
  04-Oct-24   19:03
Back Top